Dermatology Summit (Jan 12)

Staying Green in 2020

Register Now
Making a DIFference in Dermatology

The mission of the Dermatology Innovation Forum is to build a leadership community of individuals and organizations who are excited about developing ideas into products that can substantially improve skin health.

Held the day prior to the American Academy of Dermatology annual meeting, the Forum focuses on inspiring participants about innovations that can lead dermatology in its next generation of important products and services. By including physicians, researchers, inventors, investors, strategic corporate partners, service providers, government regulators, patient advocates, and other stakeholders, the Forum is a unique networking venue where leaders can communicate with, learn from, and collaborate with each other on the future of dermatology innovation.



2020 Dermatology Innovation Forum Cancelled Due to COVID-19 Outbreak

As the situation continues to rapidly evolve, there are escalating health concerns about COVID-19 (the novel coronavirus). After monitoring developments relating to this communicable disease outbreak, requesting and receiving input from various stakeholders, analyses, and deliberations, we have determined that the prudent course of action at this time is to cancel the 2020 Dermatology Innovation Forum (DIF) scheduled to be held on March 19, 2020 in Denver, CO. This decision was a difficult one and not made lightly. Please accept our sincerest apologies for the inconvenience that may have been caused by this cancellation, which after careful consideration, we have now concluded to be unavoidable.

We have considered multiple factors in reaching this decision. The most important in our view is the well-being of our attendees, exhibitors, on-site staff, others, and the greater public health community. There are many unknowns about COVID-19, and our objective in canceling the DIF is to mitigate the risk of increasing exposure to the virus through a conference setting to attendees and to those present for other reasons, such as those working at the meeting. Additionally, we seek to reduce the potential risk of secondarily exposing family, friends, patients, and others from those who would attend the meeting and could possibly be infected by COVID-19. We also seek to minimize the risk that healthcare providers attending could be restricted from doing their medical jobs should they become infected at the conference. On March 9th, the American Academy of Dermatology announced that it has cancelled its 2020 Annual Meeting scheduled to start on March 20, 2020 in Denver.

For all our attendees who have registered and for all our sponsors, emails have been sent to you directly with additional information. If you did not receive the email, or have questions, please contact Erin Conner at

Dermatology Innovation Forum Board of Directors



Olga Afanasiev, M.D., Ph.D. is a physician-scientist with a passion for problem-driven research, innovation and technology development in dermatology to improve patient care and healthcare delivery. As part of the Advancing Innovation in Dermatology & Hacking Dermatology steering committee, Dr. Afanasiev has co-organized several hackathons that have resulted in successful early stage startups. She also co-founded HealthAI, a group that brings together Stanford physicians and engineers to solve problems at scale in healthcare. Dr. Afanasiev has co-authored numerous peer-reviewed original abstracts, publications and book chapters in the areas of teledermatology, skin cancer (including melanoma and Merkel cell carcinoma), and digital health platforms to improve access and healthcare outcomes. She is currently working on technology that leverages advanced imaging with deep learning to improve remote care capabilities to enhance access, quality and value of dermatologic care.

Currently she is a practicing dermatologist at the Palo Alto Medical Foundation, Sutter Health. Her clinical and research interests include general dermatology, cutaneous oncology (melanoma, high risk non-melanoma skin cancers, Merkel cell carcinoma), teledermatology and digital health platforms. She obtained her MD/PhD with Alpha Omega Alpha honors at University of Washington in Seattle. Her graduate studies were done in Dr. Paul Nghiem's lab, where she identified how to use the immune system to fight the virus-associated Merkel cell cancer (which led to the approval to PD1 inhibitors for MCC). She obtained her BA degree from University of California, Berkeley.

Angela M. Christiano, PhD, is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics and Development at Columbia University Medical Center. She is also the Director of Basic Science Research in the Department of Dermatology at CUMC. For the past 20 years, Dr. Christiano's research has focused on understanding the molecular processes that lead to inherited skin and hair disorders in humans. Her research career began with the discovery of genetic mutations associated with epidermolysis bullosa, a skin disease that causes severe blistering. Dr. Christiano's recent work has focused on the investigation of the underlying genetic causes of and identification of potential therapies for alopecia areata, an autoimmune form of hair loss. She has published more than 300 papers in peer-reviewed journals and has trained more than 50 postdoctoral researchers and clinical fellows at Columbia University through the Program in Genetics & Development, the Institute of Human Nutrition, the Integrated Program in Cellular, Molecular and Biomedical Studies in the Graduate School of Arts & Sciences, the Clinical and Translational Science Award Program, and the Stem Cell Training Program.

Angela M. Christiano, PhD, is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics and Development at Columbia University Medical Center. She is also the Director of Basic Science Research in the Department of Dermatology at CUMC. For the past 20 years, Dr. Christiano's research has focused on understanding the molecular processes that lead to inherited skin and hair disorders in humans. Her research career began with the discovery of genetic mutations associated with epidermolysis bullosa, a skin disease that causes severe blistering. Dr. Christiano's recent work has focused on the investigation of the underlying genetic causes of and identification of potential therapies for alopecia areata, an autoimmune form of hair loss. She has published more than 300 papers in peer-reviewed journals and has trained more than 50 postdoctoral researchers and clinical fellows at Columbia University through the Program in Genetics & Development, the Institute of Human Nutrition, the Integrated Program in Cellular, Molecular and Biomedical Studies in the Graduate School of Arts & Sciences, the Clinical and Translational Science Award Program, and the Stem Cell Training Program.

Dr. Christiano was past President of the Society for Investigative Dermatology (2017), and previously served as Deputy Editor of the Journal of Investigative Dermatology. She earned her MS and PhD degrees in Microbiology and Molecular Genetics from Rutgers University.

Dr. Craw has over 20 years' experience in pharmaceutical, biotechnology and skin care research and development. Dr. Craw began his career at Merck Research Laboratories before moving to ACADIA Pharmaceuticals in San Diego, CA. Dr. Craw is a graduate of the Stanford University Graduate School of Business, Executive Management Program and holds a PhD in Chemistry from University of Manchester, England. Dr. Craw was one of the founders and primary spokesperson for Lifeline Skincare, a successful southern California-based skincare company with a unique stem cell-derived anti-aging technology. Dr. Craw is currently Senior Director of Business Development at Rodan + Fields LLC, leading the company's external research, licensing and innovation initiatives.

Tim Durso, MD, is currently a senior dermatology resident at the San Antonio Uniformed Services Health Education Consortium. He graduated with BS magna cum laude from the University of Notre Dame in 2012 and an MD summa cum laude and with research honors from the Loyola University Chicago Stritch School of Medicine in 2016. He was the first medical student ever selected by the Air Force to train directly in dermatology without serving as a general medical officer. Training at a program that serves one of the largest wounded warrior populations in the United States, Tim has encountered many unique patient problems that have necessitated innovative uses of modern dermatologic technology. For example, he was the principal investigator for a study on the use of microwave thermoablation for the treatment of residual limb hyperhidrosis in amputees. This practice environment has sparked a passion for innovation. Tim has participated as an AID scholar in the 2019-2020 Virtual Magic Wand program which focuses on identifying and defining areas of unmet need in dermatology. This training culminated in Tim serving as creator and leader of Team WartPatch (now VeraDermics Inc.), the eventual Grand Prize winner of the 2019-2020 Hacking Dermatology pitch competition. He sees continuing to strive for advancement in the field of dermatology as playing a major role in his future career as a physician-innovator.

Amanda Eisinger was born and raised in New York City before graduating from Brandeis University with a BA in Psychology. Following post-baccalaureate premedical studies, she spent several years working at Memorial Sloan Kettering Cancer Center performing clinical research involving women living with gynecologic malignancies. She subsequently completed medical school at New York Institute of Technology College of Osteopathic Medicine.

Dr. Irina Erenburg is Founder, President & CEO of Blossom Innovations, LLC. Blossom is a groundbreaking company dedicated to the discovery and development of new clinical breakthroughs in Dermatology & Aesthetics. Dr. Erenburg is a successful serial entrepreneur with extensive experience in innovation business leadership. She is a co-founder and board member of R2 Dermatology, Inc., AVAVA, Inc. and Soltego, Inc. Prior to leading Blossom Innovations, she was the Director of Strategic Transactions at the Partners HealthCare Office of Innovations, Boston’s largest hospital network and a teaching affiliate of Harvard University. There, she was responsible for execution and management of high-value deals and launch of several successful start-ups, including Zeltiq Aesthetics.

Dr. Lilit Garibyan MD, PhD is a board-certified dermatologist and a fellow in American Academy of Dermatology. She is currently an Assistant Professor at Harvard Medical School in Department of Dermatology at Massachusetts General Hospital (MGH). Dr. Garibyan is also a Physician-Scientist at the Wellman Center for Photomedicine at MGH working in Dr. Rox Anderson's laboratory as junior faculty. Her research focuses on innovative biomedical translational discoveries aimed at identifying novel treatments for dermatologic diseases and beyond. At MGH, she is also leading efforts to establish a problem-based innovation model led by clinicians interested in solving clinical problems through the MAGIC WAND Initiative. She is the co-founder of the MAGIC WAND Initiative at MGH, and the Director of the Virtual Magic Wand program. She is also the current chair of Education Committee and the Director of Innovation and External Affair at AID, where she is now leading the MAGIC WAND expansion program. Dr. Garibyan has co-authored numerous peer-reviewed original abstracts, publications and book chapters. She has lectured at a local, regional, national and international level and has developed a reputation as an expert in dermatology and innovation. Her discoveries and inventions have led to several MGH patent applications, new funding from Department of Defense and startup companies. She co-invented and developed a novel platform technology that uses injectable coolant for selective targeting of lipid rich tissue. She has also been actively involved in teaching and mentoring Harvard medical students, residents and fellows.

Dr. Garibyan received her BS summa cum laude from University of California Los Angeles, her MD from Harvard Medical School and her PhD from Harvard University in Experimental Pathology/Immunology.

Myriam Golembo is VP Regulatory Affairs and Dermatology at BiomX, a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. She has been leading the development of BX001 a topical gel for acne-prone skin for the past 2.5 years into the recently initiated clinical study. Myriam holds a PhD in Molecular Genetics from the Weizmann Institute and has over 15 years' experience in the biotech industry. Prior to BiomX, she was VP regulatory and clinical operations at a company developing immunotherapy for cancer and viral disease, and VP product development at a company developing new formulated antibiotics for ear, nose and throat. Previous to these, she served as Director of Products Development at Protalix, a company developing and marketing FDA approved recombinant therapeutic proteins with clinically improved profiles produced in a plant cell-based protein expression platform, where she focused in regulatory and clinical development.

Dr. Halpern is an internationally recognized expert in melanoma and pigmented lesions. He has served as co-Chairman of the National Council for Skin Cancer Prevention and is currently Chief of the Dermatology Service and co-leader of the Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Center. Dr. Halpern has contributed to our understanding of melanoma prevention, prognosis, and risk stratification as well as the natural history of melanocytic tumor progression in humans. Dr. Halpern has been a pioneer in the application of imaging technologies to dermatology research and clinical care. His clinical team has been at the forefront of the use of total body photography (TBP), dermoscopy, and reflectance confocal microscopy (RCM) for melanoma surveillance, diagnosis, and surgical management. The optical engineering laboratory established by Dr. Halpern and led by Dr. Rajadhyaksha invented the technologic underpinnings of hand-held in vivo reflectance RCM and played a central role in establishing RCM as an important adjunct to clinical care. Dr. Halpern initiated and leads the International Skin Imaging Collaboration (ISIC). Under his leadership, ISIC has become the international focal point for developing standards for skin imaging and the nexus of efforts in the application of artificial intelligence to the diagnosis of skin cancer.

John E. Harris, MD, PhD, is a tenured Associate Professor of Dermatology at the University of Massachusetts Medical School (UMMS) in Worcester, MA. He serves as Director of the Vitiligo Clinic and Research Center at UMMS, focusing both on the clinical management of vitiligo patients as well as research into new therapeutic strategies. His approach includes the seamless integration of basic, translational, and clinical studies that incorporate the use of mouse models, human tissues, and clinical trials that determine disease mechanisms of vitiligo, identify quantifiable markers of disease activity, and test new treatments.

Previous work from his research team highlighted the central role that the IFN- signaling pathway plays in both the progression and maintenance of vitiligo, and recent studies in both mice and humans have demonstrated efficacy of new immunotherapies that target this pathway. Early clinical trials in vitiligo using this strategy look promising, and more are being developed. Recent work from his lab revealed that targeting the IL-15 signaling pathway not only results in reversal of disease, but durable, long-lasting improvement. As a result of this work, Dr. Harris acquired Series A funding to further develop this approach as a new treatment for vitiligo and founded Villaris Therapeutics, whose entire focus is to develop an effective, long-lasting treatment for vitiligo.

Ongoing research seeks to better characterize the mechanism of action of these new treatments and to identify new targets in order to design an optimal therapeutic strategy for vitiligo patients, who currently have no FDA-approved treatment options. Long-term goals are to bring new treatments with better safety and efficacy into the clinic, to develop more durable, long-lasting therapies, and ultimately to find a cure for this psychologically devastating disease.

Michael Howell currently works as the Senior Director of Translational Research at the Incyte Corporation with a focus on immunological and inflammatory diseases. Dr. Howell received his PhD in Immunology from West Virginia University School of Medicine and completed his post-doctoral training at National Jewish Health. While at National Jewish, Michael transitioned to the faculty and served as a Co-Investigator for the Atopic Dermatitis Vaccinia Network. Since transitioning to industry, Dr. Howell has held positions at Boehringer Ingelheim, the Immune Tolerance Network, and MedImmune/AstraZeneca. Throughout his career, Dr. Howell has combined clinical, translational, and basic science approaches to identify personalized medicine approaches to treat inflammatory and immunological diseases. This has been highlighted in national and international meetings, publications, and patents for therapeutic interventions and biomarker strategies.

Edward Hsia, PhD is currently VP, External Research & Innovation, at Almirall where he leads the identification and evaluation of early stage external innovation opportunities. Dr. Hsia is responsible for developing a network within academia, research institutions, biotech/pharma companies, and start-up firms that will ultimately help strengthen Almirall’s early stage pipeline. Dr. Hsia has been in the dermatology field since 2004. Beginning with Connetics and through acquisitions by Stiefel and GSK, Dr. Hsia gained increasing responsibilities in the areas of research and early development. Just prior to joining Almirall in 2017, Dr. Hsia was Executive Director at Allergan where he led the research effort in medical dermatology. Dr. Hsia holds a B.S. in Biological Sciences from UC Davis, and a PhD in Biochemistry from Boston University.

Junming Hu is a member of Tracksore and works as a Data Analyst in Boston University School of Medicine. Junming holds a master's degree in Bioinformatics from Boston University. He specializes in data analysis with special interest in Alzheimer's Disease. Junming's working experience inspired him to apply machine learning algorithm to improve medical care. When Junming isn't hacking medicine, he enjoys flying his drone to capture beautiful foliage in New England. Trying to see the world in different ways is what he wants to do!

Sinyoung Jeong, PhD is currently a postdoctoral research fellow in the laboratory of Dr. Conor Evans at the Wellman Center for Photomedicine at Massachusetts General Hospital/Harvard Medical School. Here, he works on developing pharmacokinetic tomography through visualizing and quantifying cutaneous drug uptake within the skin, using advanced spectroscopic imaging microscopy techniques such as fluorescence lifetime imaging microscopy and coherent Raman scattering microscopy. He has also been pursuing multidisciplinary research focused on developing in vitro, ex vivo, and in situ multiplexed optical molecular imaging tools used alongside multifunctional nanoparticles. He obtained his BS and PhD in chemistry from the Seoul National University in the Republic of Korea.

Dina Katabi is the Andrew & Erna Viterbi Professor of Electrical Engineering and Computer Science at MIT. She is also the director of the MIT's Center for Wireless Networks and Mobile Computing, a member of the National Academy of Engineering, and a recipient of the MacArthur Genius Award. Professor Katabi received her PhD and MS from MIT in 2003 and 1999, and her Bachelor of Science from Damascus University in 1995. Katabi's research focuses on innovations in mobile computing, wireless sensing, and machine learning with application to digital health. Her research has been recognized with ACM Prize in Computing, the ACM Grace Murray Hopper Award, the SIGCOMM test of Time Award, the Faculty Research Innovation Fellowship, a Sloan Fellowship, the NBX Career Development chair, and the NSF CAREER award. Her students received the ACM Best Doctoral Dissertation Award in Computer Science and Engineering twice. Further, her work was recognized by the IEEE William R. Bennett prize, three ACM SIGCOMM Best Paper awards, an NSDI Best Paper award, and a TR10 award. Several start-ups have been spun out of Katabi's lab such as PiCharging and Emerald.

Dr. Xiaoxiao Li is a PGY-3 dermatology resident at University of Pittsburgh Medical Center (UPMC). Prior to residency, she obtained her MD/PhD degrees from UT Southwestern in Dallas, TX and completed her intern year in internal medicine at NYU Langone Medical Center in NYC. Dr. Li is interested in medical innovation, angel/venture investing and entrepreneurship. In particular she is interested in wearable devices that can track skin health. She has been an angel investor in a healthcare start-up company and has participated in several healthcare Hackathons. Dr. Li is a member of the Advancing Innovation in Dermatology (AID) Virtual Magic Wand (VMW) scholars' class 2019-2020.

Michelle is a Stanford-trained physician and entrepreneur driven to improve human health through advances in technology. Prior to founding Medable in 2014, Michelle was a Howard Hughes Research Fellow. She is a board-certified dermatologist who continues to practice today.

Art Papier MD is a founder of VisualDx and CEO. A dermatologist, Art has a particular interest in designing clinical systems that leverage the human ability for pattern recognition, thereby increasing clinical accuracy and reducing diagnostic error at the point of care. In line with this goal, he has led the development of VisualDx, the first diagnostic clinical decision support system to be widely used, and to incorporate machine learning for skin rashes and lesions. Art is also passionate about the engagement of people in their medical decisions, in consumer health, and developing tools to educate and empower patients in their homes and on their mobile devices. The focus of his work is to assist medical decisions by professionals and people alike, with decision support and AI augmenting human intelligence.

A graduate of Wesleyan University, Art received his MD from the University of Vermont College of Medicine and completed his graduate medical training at the University of Rochester Medical Center. He is also an Associate Professor of Dermatology and Medical Informatics at the University of Rochester School of Medicine and Dentistry.

Dr. Payne is a tenured Associate Professor of Dermatology at the University of Pennsylvania. She received her BS in Biology from Stanford University and her MD/PhD from Washington University School of Medicine, followed by residency and postdoctoral fellowship training in Dermatology at the University of Pennsylvania. Her clinical practice focuses on autoimmune skin diseases, with particular focus on the autoimmune blistering disease pemphigus. Her laboratory research has focused on understanding how B cell autoimmunity occurs in patients in order to develop precision medicine therapies for disease. Dr. Payne has received several honors for her work, including the Charles and Daneen Stiefel Scholar Award, a "Top 10" Clinical Research Forum Award, and election to the American Society for Clinical Investigation. At Penn, Dr. Payne also serves as Director of the NIH-funded Autoimmunity Center of Excellence, Core Director for the NIH-funded Skin Biology and Diseases Resource-based Center, Associate Director of the Medical Scientist Training Program, and faculty advisor for the Association of Women Student MD-PhDs. Outside of Penn, she serves on the Medical Advisory Council of the IPPF, the NIH/NIAMS Board of Scientific Counselors, and is co-founder and co-chair of the Scientific Advisory Board at Cabaletta Bio, Inc., focused on targeted cellular immunotherapy of B cell-mediated diseases.

In 1997 Dan Piacquadio founded Therapeutics Inc., a specialty pharmaceutical development company focused on novel treatments for cutaneous and mucosal diseases. Since 2001, Therapeutics Inc. (TI) has existed as a fully integrated product development CRO from product concept through FDA approval (i.e. program management, non-clinical, clinical, regulatory affairs and CMC). Currently TI manages 8 -12 development programs annually. TI focuses on dermatology as well as other therapeutic areas including would healing, women’s health, pediatrics, and GI among others. Dr. Piacquadio is currently President and CEO of Therapeutics Inc., and as such, leads the development team and serves as the medical monitor on Phase I-IV IND and IDE studies for a broad range of indications and dosage forms. In the past five years alone, Therapeutics has filed over 12 IND/IDEs, achieved multiple drug approvals and has been responsible for managing over 80 studies in approximately 12,000 subjects. In addition, Dr. Piacquadio has been a consultant to the FDA office of generic drugs.

Dr. Piacquadio received his undergraduate BS from Rensselaer Polytechnic Institute in Biomedical Engineering and his medical degree from the University of Pennsylvania. He has been involved in clinical research and medical product development since 1985; initially as Director of R&D for Oncotherm (a specialty biotechnology company specializing in the use of chemotherapy in conjunction with hyperthermia for the treatment of cancer), with primary responsibility for regulatory affairs and clinical development. Following Oncotherm, Dr. Piacquadio was involved with a number of start-up biotech ventures and then trained in dermatology, subsequently joining the Division of Dermatology at the University of California, San Diego and served as director of this dermatopharmacology and clinical research facility from 1989 to 1997. He has participated as the principal investigator in an extensive number of trials in most dermatologic conditions, including but not limited to: acne, anti-infectives (viral, bacterial, etc.), hair growth and removal, inflammatory skin diseases, hypertropic scars, soft tissue augmentation, dermatophyte diseases, dyschromia, photoaging, neoplastic conditions, and wound healing, among others.

Adam Raff, M.D., Ph.D. is the Director of Translational Medicine at LEO Pharma. He is a board-certified dermatologist and physician-scientist. He previously worked at the Massachusetts General Hospital (MGH) on developing point-of-care diagnostics for infectious and inflammatory diseases of the skin. He received his undergraduate degree in biology and biochemistry from Georgetown University summa cum laude with Phi Beta Kappa honors. He received his MD with Alpha Omega Alpha honors and his PhD with Phi Kappa Phi honors in Systems Biology and Disease under W. Martin Kast PhD at the University of Southern California. Dr. Raff completed his dermatology residency at Harvard and his post-doctoral fellowship as an NIH-funded T32 fellow under R. Rox Anderson MD at the Wellman Center for Photomedicine at MGH. Dr. Raff was a founding member of the Education Committee for Advancing Innovation in Dermatology (AID), a non-profit organization. He previously served as AID Education Committee Chair and Virtual Magic Wand Co-Chair, and currently serves as the Director of the Hacking Dermatology Initiative.

Dennis R. Roop received a B.A. degree in Biology from Berea College, Berea, KY in 1969 and a M.S. and Ph.D. in Microbiology from the University of Tennessee, Knoxville, TN in 1972 and 1977, respectively. Following a postdoctoral fellowship at Baylor College of Medicine, Houston, TX (1977 to 1980), he was recruited to the National Cancer Institute, National Institutes of Health, Bethesda, MD, where he rose to the rank of Senior Investigator. In 1988, he was recruited back to Baylor College of Medicine, where he held the positions of Professor of Molecular and Cellular Biology and Dermatology and Director of the Center for Cutaneous Molecular Biology until the end of 2006. In January, 2007, he was recruited to the University of Colorado School of Medicine as the founding Director of the Charles C. Gates Center for Regenerative Medicine. He is Professor of Dermatology and holds the Charles C. Gates Chair of Regenerative Medicine. He is also founding Director of the Gates Biomanufacturing Facility, a state-of-the-art current Good Manufacturing Practices (cGMP) facility, which opened in April, 2015 and manufactures US Food and Drug Administration (FDA) approved investigational regenerative medicine products for early phase clinical trials.

Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline’s Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.

Mr. Smith, a corporate lawyer focusing on intellectual property transactions, venture financings and regulatory matters for life sciences companies and investors, is of Counsel with Pepper Hamilton LLP, resident in its Pittsburgh office. He is a member of the firm's Health Sciences Department. Mr. Smith's intellectual property-related work includes IP transactions, regulatory issues and licensing. His corporate practice is concentrated in the organization, financing and growth of life sciences companies, and he is an authority on the legal issues surrounding the use of human biological materials. He frequently speaks at universities and trade conferences on commercial development of tissue, cell and gene technologies.

Mr. Smith is active in a number of trade organizations and scientific societies. He is a Fellow of the Tissue Engineering and Regenerative Medicine International Society. Mr. Smith is a graduate of Hamilton College (A.B. 1977) and American University, Washington College of Law (J.D. 1980). He is admitted to practice in Pennsylvania.

Kumar Sukhdeo is a physician-scientist trained as a stem cell biologist and hair specialist dermatologist. He completed his undergraduate degree at Duke University, followed by a formative translational research experience at the Dana-Farber Cancer Institute. Dr. Sukhdeo continued in Cleveland, Ohio to complete his medical (MD) and graduate (PhD) degrees at Case Western Reserve University and Cleveland Clinic. His PhD thesis concentrated on stem cell signaling pathways and regenerative applications, which continues as his primary research interest. He completed his dermatology residency at NYU prior to founding OnDERMAND Dermatology.

Dr. Tang is a Professor of Dermatology at Stanford University School of Medicine. She received her MD and PhD (Biophysics) from Stanford in 2003. Dr. Tang’s research focuses on the clinical development of novel therapeutics for rare monogenetic skin diseases such as Basal Cell Nevus (Gorlin) Syndrome and Epidermolysis Bullosa. Dr. Tang and her colleagues showed that Hedgehog pathway inhibition could dramatically shrink Basal Cell Carcinoma tumors in patients with Gorlin Syndrome in randomized clinical trials. Her work has helped start companies who are testing topical Patidegib gel (PellePharm Inc) and itraconazole in Gorlin Syndrome. For conflict of interest, Dr. Tang is a co-founder and advisor to PellePharm and has a patent on itraconazole and BCCs. Dr. Tang also leads the clinical trials of keratinocyte skin grafts (EB-101 licensed to Abeona). These gene-corrected grafts were granted FDA’s Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation.

Reid Waldman is a co-founder of Team WartPatch, this year's Hacking Dermatology Grand Prize winner. At Team WartPatch, which now operates as VeraDermics Inc., Reid helps direct the company’s strategic vision and is currently working to secure additional seed funding for the company. While VeraDermics is Reid's start-up debut, he has previous innovation experience as a 2019-2020 AID Virtual Magic Wand Scholar. Reid met two of his co-founders at VeraDermics through the AID Scholar program. Reid is also a 2nd year dermatology resident at the University of Connecticut. At UConn, Reid helps run the Clinical Trials Unit and he has independently received grant funding as a principle investigator for his research. As a resident, Reid has published nearly 100 academic works that range from original research to humanities commentary. Before moving to CT, he was born and raised in Kansas where he lived until graduating from the University of Missouri-Kansas City 6 Year BA/MD combined program at the age of 23. While in Kansas, Reid was a certified BBQ judge who trained at The American Royal.

Ke Xu is a member of Tracksore and is an MD/PhD student at Boston University School of Medicine. Ke is currently in his third year of PhD training in Bioinformatics, specializing in transcriptomic analysis for early cancer detection. Previously, Ke has worked at Memorial Sloan Kettering Cancer Center as a microscopy specialist for four years focusing on image acquisition and analysis. In his spare time, he enjoys eating and cooking food from all over the world, playing computer games (Age of Empires II), and photography, which became the basis of ideas used for Tracksore.

Steve Xu MD, MSc is a Harvard-trained physician-engineer, inventor, entrepreneur, board-certified dermatologist, and academic. Currently, he is the Medical Director of the Center of Bio-Integrated Electronics (CBIE) at Northwestern University and an Assistant Professor in the Department of Dermatology at Northwestern University’s Feinberg School of Medicine.

He received his undergraduate degree in bioengineering from Rice University summa cum laude, a Masters in Health Policy, Planning, and Finance with Merit from The London School of Economics where he was a Marshall Scholar, and an MD from Harvard Medical School with special honors where he was a Soros Fellow. He completed his residency training in dermatology at the McGaw Medical Center of Northwestern University where he still actively practices.

Throughout his career, Dr. Xu has developed numerous medical technologies that span multiple medical fields including dermatology, orthopedics, cardiology and consumer health. He is a core developer of the ANNE® Vital Signs Monitoring System commercialized through Sibel Health where he is a co-founder and CEO. His work has been supported by industry, philanthropy, and the National Institutes of Health. Dr. Xu is an inventor on more than a dozen patents and has authored more than 75 peer-reviewed publications. His work has appeared in The New England Journal of Medicine, Science, and Nature with coverage from media sources such as The New York Times, CNN, The Washington Post, and The Los Angeles Times. He is externally recognized expert on medical innovation and digital health.




Registration and Networking



  • William Ju, MD, FAAD
  • President & Founding Trustee , Advancing Innovation in Dermatology, Inc.

Featured Speaker

  • Jean Tang, MD, PhD, FAAD
  • Professor of Dermatology , Stanford University

Session #1 - What's the Future?

  • Angela Christiano, PhD, FACMG
  • Vice-Chair of Research, Departments of Dermatology and Genetics & Development , Columbia University
  • Past President , Society of Investigative Dermatology
  • Edward Hsia, PhD
  • Vice President, External Research & Innovation , Almirall
  • Lilit Garibyan, MD, PhD, FAAD
  • Assistant Professor , Harvard Medical School
  • Physician-Scientist , Wellman Center for Photomedicine at Massachusetts General Hospital
  • Myriam Golembo, PhD
  • Vice President of Regulatory Affairs and Dermatology , BiomX
  • John E. Harris, MD, PhD, FAAD
  • Associate Professor of Dermatology , University of Massachusetts Medical School
  • Aimee Payne, MD, PhD, FAAD
  • Associate Professor of Dermatology , University of Pennsylvania
  • Dennis Roop, PhD, MS
  • Professor of Dermatology , University of Colorado School of Medicine

Session #2 - Precision Medicine

  • Michael L. Sierra, PhD
  • Vice President , LEO Science & Tech Hub
  • Michael D. Howell, PhD
  • Senior Director, Translational Research , Incyte Corporation
  • Sinyoung Jeong, PhD
  • Postdoctoral Research Fellow , Wellman Center for Photomedicine at Massachusetts General Hospital/Harvard Medical School
  • Dina Katabi, PhD, MS
  • Andrew & Erna Viterbi Professor of Electrical Engineering and Computer Science , Massachusetts Institute of Technology
  • Daniel Piacquadio, MD, FAAD
  • Founder, Chief Executive Officer & President , Therapeutics, Inc.

Networking Break


Featured Speaker

  • Michelle Longmire, MD
  • Chief Executive Officer , Medable

Session #3 - Devices and Technology

  • Steve Xu, MD, MSc, FAAD
  • Medical Director of the Center of Bio-Integrated Electronics , Northwestern University
  • Assistant Professor in the Department of Dermatology , Northwestern University Feinberg School of Medicine
  • Allan Halpern, MD, MSc, FAAD
  • Chief of the Dermatology Service , Co-Leader of the Melanoma Disease Management Team , Memorial Sloan Kettering Cancer Center
  • Art Papier, MD, FAAD
  • Founder & Chief Executive Officer , VisualDx

Featured Sponsor

  • Simon Craw, PhD
  • Senior Director of Business Development , Rodan + Fields LLC

Session #4 - Hacking Dermatology

  • Olga Afanasiev, MD, PhD, FAAD
  • Co-Founder , HealthAI
  • Dermatologist , Private Practice Dermatology
  • Adam Raff, MD, PhD, FAAD
  • Director, Translational Medicine , LEO Pharma
Blossom Innovations, LLC 
  • Irina Erenburg, PhD
  • President & Chief Executive Officer , Blossom Innovations, LLC.
  • Xiaoxiao Li, MD, PhD
  • Dermatology Resident , University of Pittsburgh Medical Center
  • Amanda Eisinger, DO
  • Investigative Dermatology Research Fellow , OnDermand
  • Kumar Sukhdeo, MD, PhD
  • Physician-Scientist , OnDermand
  • Junming Hu
  • Data Analyst , Boston University School of Medicine
  • Ke Xu,
  • MD, PhD Candidate (G3) , Boston University School of Medicine
  • Tim Durso, MD
  • Dermatology Resident , San Antonio Uniformed Services Health Education Consortium
  • Reid Waldman, MD
  • Dermatology Resident , University of Connecticut

Featured Sponsor

  • David Smith, JD
  • Of Counsel , Pepper Hamilton LLP

Summary and Close


Networking Reception



Conference Board of Directors

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development of global leading brands in medical dermatology, aesthetics, and other therapeutic areas including Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children's Skin Disease Foundation and Camp Wonder. He is a board of directors member and co-founder of Advancing Innovation in Dermatology, and the Dermatology Summit and Dermatology Innovation Forum conferences.

John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $2B+ in assets under management.

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of EdWiser, Inc. (now known as Zoomi, Inc.), is currently a member of the board of directors for Brickell Biotech, Inc., and serves on the Advisory Council for the Keller Center for Innovation Engineering Education at Princeton University.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Dr. Walker co-founded Aclaris Therapeutics, Inc. and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 20 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and continues to serve on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine.

Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).

He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.



For Sponsorship Opportunities, please contact Rhonda Ware at


The Dermatology Innovation Forum utilizes a conference app for meeting materials and networking appointments, available on both Apple and Android devices for all registered attendees.

This app will also serve as our networking portal. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.

Our app will launch in February, and you will receive an email at that time with download instructions.



Event Details

Erin Conner, CMP
Eclipse Meeting Productions, LLC
A Compass Group Partners Company

Sponsorship Opportunities

Rhonda Ware, HMCC
Eclipse Meeting Productions, LLC
A Compass Group Partners Company

Confirmed Speakers

Melanie Conner
Eclipse Meeting Productions, LLC
A Compass Group Partners Company

Click here for Confirmed Speaker Deliverables

Venue Details

The Ritz-Carlton Hotel
1881 Curtis Street
Denver, CO 80202
Hotel Website


Frequently Asked Questions

What is the agenda for the conference?

The current program agenda can be found here.

What is the cost of registration?

  • If registered by December 5, 2019 - $185 Physicians and Academicians / $445 Industry
  • Registration after December 5, 2019 - $245 Physicians and Academicians / $595 Industry

What is included in the registration fees?

Conference registration includes:

  • Networking Café
  • Networking Breaks
  • All Conference Sessions
  • Access to Conference App for Networking Opportunities
  • Evening Networking Cocktail Reception

How do I become a Sponsor?

If you are interested in a sponsorship opportunity, please contact Rhonda Ware at, for the sponsorship overview and level pricing.


Our app will launch in February, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.

Where can I make hotel reservations?

If you will be attending the Annual AAD conference, you will need to visit the 2020 Annual Meeting website at to request hotel accommodations. If you are not attending the Annual AAD Conference, a list of local hotels will be available at

What is the dress code?

Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.

I am a Sponsor. How do I redeem my contracted complimentary registration(s)?

After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by February 14, 2020. If you have not yet received the email, please contact us at

Cancellation Policy

Requests for registration fee cancellations for the conference must be received on or before February 18, 2020 by 3pm Eastern Time. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on February 18, 2020. Written notice of your cancellation should be sent to with a copy to

Force Majeure

No damages or refunds shall be due for a failure of performance by the occurrence of any contingency beyond the reasonable control of AID or Eclipse Meeting Productions. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, failure or delay in transportation, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.

Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.